Drugs / Mosliciguat
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07185321 | Jun 2025 | — | Pulmovant, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07333183 | Dec 2025 → Dec 2026 expected | interstitial lung disease, pulmonary hypertension | Pulmovant, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06635850 | Oct 2024 → Dec 2026 expected | interstitial lung disease, pulmonary hypertension | Pulmovant, Inc. | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Pulmovant, Inc. | Results Pulmovant Announces Positive Results from Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study pulmovant.com ↗
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever reported PVR reduction in any randomized controlled PH trial |
| 2025-09-04 | Pulmovant, Inc. | Regulatory Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) pulmovant.com ↗
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) |
| 2025-06-16 | Pulmovant, Inc. | Results Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics pulmovant.com ↗
These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients. |
| 2024-09-10 | Pulmovant, Inc. | Results Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress pulmovant.com ↗
Once-daily dosing via dry powder inhaler (DPI) was well tolerated, with low rates of treatment-emergent adverse events (TEAEs) |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mosliciguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06635850 ↗ |
| Route | Inhaled | “Dose level 1, 2, or 3 for inhalation” NCT06635850 ↗ |